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Nesfatin-1 is well-established to induce an anorexigenic effect. Recently, nesfatin-130−59,
was identified as active core of full length nesfatin-11−82 in mice, while its role in
rats remains unclear. Therefore, we investigated the effects of nesfatin-130−59 injected
intracerebroventricularly (icv) on the food intake microstructure in rats. To assess whether
the effect was also mediated peripherally we injected nesfatin-130−59 intraperitoneally
(ip). Since obesity affects the signaling of various food intake-regulatory peptides we
investigated the effects of nesfatin-130−59 under conditions of diet-induced obesity (DIO).
Male Sprague–Dawley rats fed ad libitum with standard diet were icv cannulated and
injected with vehicle (5µl ddH2O) or nesfatin-130−59 at 0.37, 1.1, and 3.3µg (0.1, 0.3,
0.9 nmol/rat) and the food intake microstructure assessed using a food intake monitoring
system. Next, naïve rats were injected ip with vehicle (300µl saline) or nesfatin-130−59
(8.1, 24.3, 72.9 nmol/kg). Lastly, rats were fed a high fat diet for 10 weeks and those
developing DIO were icv cannulated. Nesfatin-1 (0.9 nmol/rat) or vehicle (5µl ddH2O)
was injected icv and the food intake microstructure assessed. In rats fed standard diet,
nesfatin-130−59 caused a dose-dependent reduction of dark phase food intake reaching
significance at 0.9 nmol/rat in the period of 4–8 h post injection (−29%) with the strongest
reduction during the fifth hour (−75%), an effect detectable for 24 h (−12%, p < 0.05 vs.
vehicle). The anorexigenic effect of nesfatin-130−59 was due to a reduction in meal size
(−44%, p < 0.05), while meal frequency was not altered compared to vehicle. In contrast
to icv injection, nesfatin-130−59 injected ip in up to 30-fold higher doses did not alter food
intake. In DIO rats fed high fat diet, nesfatin-130−59 injected icv reduced food intake in
the third hour post injection (−71%), an effect due to a reduced meal frequency (−27%,
p < 0.05), while meal size was not altered. Taken together, nesfatin-130−59 is the active
core of nesfatin-11−82 and acts centrally to reduce food intake in rats. The anorexigenic
effect depends on themetabolic condition with increased satiation (reduction inmeal size)
under normal weight conditions, while in DIO rats satiety (reduction in meal frequency) is
induced.
Keywords: anorexigenic, brain-gut-axis, NUCB2, satiation, satiety
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INTRODUCTION
Nesfatin-11−82 was discovered in 2006 by Mori et al. as an
anorexigenic peptide derived from the rat brain (Oh-I et al.,
2006). It is post-translationally processed from the gene encoding
nucleobindin2 (NUCB2) by the pro-hormone-convertase 1/3
(Oh-I et al., 2006). NUCB2 consists of a 24 amino acid
N-terminal signal peptide and a protein structure containing
396 amino acids, but only the 396 amino acid sequence is
cleaved into the N-terminal nesfatin-11−82, nesfatin-285−163, and
the C-terminal nesfatin-3166−396 (Oh-I et al., 2006). It was
shown that nesfatin-11−82, but not nesfatin-285−163 or nesfatin-
3166−396, reduces food intake and body weight gain in rats after
injection into the third brain ventricle (Oh-I et al., 2006). The
anorexigenic effect of central nesfatin-11−82 injected into the
lateral, third and fourth brain ventricle, into the cisterna magna
or directly into the lateral hypothalamic area, the paraventricular
nucleus, or the dorsal vagal complex has been confirmed by
various independent groups in several studies in rats (Yosten
and Samson, 2009, 2010; Chen et al., 2012; Könczöl et al., 2012;
Xia et al., 2012; Dong et al., 2014), mice (Atsuchi et al., 2010;
Goebel et al., 2011), and goldfish (Gonzalez et al., 2010; Kerbel
and Unniappan, 2012). This converging evidence points toward
a physiological role of nesfatin-11−82 in the regulation of food
intake.
Following these initial studies, the anorexigenic effect of
nesfatin-1 was further characterized investigating the underlying
food intake microstructure providing deeper insight into the
mechanisms underlying the reduction of food intake (Geary,
2005). In mice, nesfatin-11−82 injected intracerebroventricularly
(icv) reduced food intake with a delayed onset, an effect
due to a reduction in meal size and meal frequency (Goebel
et al., 2011) indicating a stimulatory effect on satiation
and satiety (Strubbe and Woods, 2004). However, as species
differences often play a role, this characterization is pending in
rats.
Recently, the active core of nesfatin-11−82 has been identified,
namely the mid fragment nesfatin-130−59 (Shimizu et al.,
2009), while the N-terminal nesfatin-11−29, and the C-terminal
nesfatin-160−82 had no anorexigenic effect in mice (Shimizu
et al., 2009; Stengel et al., 2012a). Although it is not clear
yet whether this processing occurs in vivo, the characterization
is an important step toward a better understanding of the
ligand-receptor interaction, keeping in mind that the nesfatin-
1 receptor remains to be identified. Again, the characterization
of the anorexigenic effect of nesfatin-130−59 is lacking for
rats.
After the initial identification of NUCB2/nesfatin-1 in
the brain, NUCB2 mRNA, and NUCB2/nesfatin-1 protein
expression was also detected in the periphery (Stengel et al.,
2009b). Interestingly, the major source of NUCB2/nesfatin-1 is
the stomach with much higher NUCB2 mRNA expression levels
compared to the brain (Stengel et al., 2009b) likely to act as
a gut-brain peptide, a hypothesis supported by the observation
that nesfatin-1 is able to cross the blood-brain barrier (Pan
et al., 2007). Interestingly, on a cellular level NUCB2/nesfatin-
1 is co-expressed with ghrelin, the major orexigenic peptide
signaling from the gut to the brain (Al Massadi et al., 2014),
within the same cells in rats (Stengel et al., 2009b), and humans
(Stengel et al., 2013a). This led to the assumption that these
endocrine cells in the stomach can regulate food intake in both
directions, either stimulate via the release of ghrelin or inhibit
via the release of NUCB2/nesfatin-1 (Stengel and Taché, 2012b).
However, data on the peripheral effects of nesfatin-1 on food
intake are inconsistent. While several studies observed no effects
of nesfatin-1 on food intake in rats (Stengel et al., 2009a) or mice
(Goebel et al., 2011), one study described an anorexigenic effect
of nesfatin-130−59 following intraperitoneal (ip) injection of high
doses inmice (Shimizu et al., 2009). However, no data in rats exist
so far.
The therapeutic potential of NUCB2/nesfatin-1 was discussed
in several review articles (Stengel et al., 2013b), especially in the
light of its leptin-independent signaling pathway (Oh-I et al.,
2006), a hormone known to be less active under conditions
of obesity (also known as leptin resistance) (Crujeiras et al.,
2015). However, a detailed characterization of the food intake
microstructure under conditions of diet-induced obesity (DIO),
a well-established animal model for alimentary obesity (Lutz
and Woods, 2012) frequently found in humans, has not been
performed yet.
Therefore, the aims of the current study were to investigate
the effect of icv injected nesfatin-130−59 on the food intake
microstructure in normal weight rats. Next, we investigated
whether the effect could also be observed following ip injection
in rats. Lastly, to characterize the effect of nesfatin-130−59
on the food intake microstructure in obese animals, DIO




Male Sprague–Dawley rats (Harlan-Winkelmann Co., Borchen,
Germany) weighing 280–350 g were first group housed (4
rats/group) under controlled illumination (06.00–18.00 h) and
temperature (21–23◦C). During this time rats were handled
daily to become accustomed to the interaction with the
investigators (daily control of body weight, light hand restraint
for subsequent icv, or ip injections). Rats had ad libitum
access to standard rodent diet (D12450B, Research Diets, Inc.,
Jules Lane, New Brunswick, NJ, USA) and tap water. Animal
care and experimental procedures followed institutional ethics
guidelines, conformed to the requirements and were approved
by the state authority for animal research conduct (Landesamt
für Gesundheit und Soziales Berlin, LaGeSo Berlin; animal
protocol # G 0131/11).
Peptides
Rat nesfatin-130−59 (Bachem AG, Weil am Rhein, Germany)
was aliquoted in sterile distilled water and stored at –80◦C until
further use. Purity was assessed by HPLC and mass spectroscopy
(manufacturer’s information). Directly before administration, rat
nesfatin-130−59 was further diluted in sterile ddH2O for icv
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injection or in sterile 0.9% saline (B. Braun AG, Melsungen,
Germany) for ip injection to reach the final concentrations
detailed below.
Diets
For the induction of DIO, rats were fed a high fat diet (D12451,
45% calories from fat, 35% from carbohydrates, and 20% from
protein, 4.7 kcal/g diet, Research Diets Inc.) for a period of
10 weeks. Control rats were kept on a standard rodent diet
(D12450B, 10% calories from fat, 70% from carbohydrates, and
20% from protein, 3.9 kcal/g diet, Research Diets Inc.). Body
weight and food intake were assessed daily. At the end of the
10-week feeding period, the 50% of rats gaining the most body
weight were selected as DIO.
Intracerebroventricular Cannulation
Rats were chronically icv cannulated as described before
(Stengel et al., 2010a,b). Briefly, rats were anesthetized with
an ip injection of 100mg/kg ketamine (Ketanest™, Curamed,
Karlsruhe, Germany) and 10mg/kg xylazine (Rompun™, 2%,
Bayer, Leverkusen, Germany). Afterwards, rats were placed in
a stereotactic apparatus to implant a chronic 22-gauge guide
cannula into the right lateral brain ventricle. The coordinates
for the placement (from bregma: 0.8mm posterior, 1.5mm right
lateral, and 3.5mm ventral) were based on the atlas of Paxinos
and Watson (2006). The chronic 22-gauge guide cannula was
fixed by dental cement, anchored by four sterile screws (Plastic
One Inc., Roanoke, VA, USA), and the wound was sutured. After
the surgery, animals were housed individually and allowed to
recover for 5 days. During this time, rats were handled daily
to adapt to the icv injection procedure (light hand restraint for
1min). For the icv injection a 28-gauge cannula was connected
to a 25µl Hamilton syringe by a PE-50 tube (BD intramedic
polyethylene tubing, Clay Adams, NJ, USA) and a volume of
5µl was injected over a period of 1min into the conscious
rat.
The correct placement of the cannula was verified after
the experiments by injecting 5µl of 0.1% toluidine blue and
visualizing the spreading of the dye throughout the brain
ventricular system. No animals had to be excluded due to
erroneous placement of the cannula.
Automated Food Intake Monitoring
The BioDAQ episodic food intake monitoring system (BioDAQ,
Research Diets Inc.) was used to investigate the food intake
microstructure in rats. This system has been established before
for the use in mice (Goebel et al., 2011) and recently also rats
(Teuffel et al., 2015).
Rats were habituated for 1 week to the single housing (in
regular housing cages with normal bedding and enrichment)
and feeding from the hopper and as shown before quickly
adapted to these conditions within 2–3 days indicated by
normal food intake and regular body weight gain (Teuffel
et al., 2015). Water was provided ad libitum from regular water
bottles. Food was provided in low spill food hoppers placed
on a balance. The “bridging phenomenon,” that occurs when
retained food spillage underneath the gate causes erroneous
measurements, was observed very rarely by use of the diet
described above and daily maintenance (cleaning) of the
hoppers.
The BioDAQ food intake monitoring system weighs the
hopper with food (±0.01 g) every second and detects “not eating”
as weight stable and “eating” as weight unstable. “Feeding bouts,”
defined as change in stable weight before and after an event,
are recorded as vectors with starting time, duration and amount
of food consumed (Teuffel et al., 2015). The feeding bouts are
separated by an inter-bout interval (IBI) and meals can consist
of one or more bouts. Furthermore, meals are separated by
inter-meal intervals (IMI), in rats defined by a duration of
15min (Teuffel et al., 2015). The minimum meal size in rats
was defined as 0.01 g and therefore food intake was considered
as one meal when the feeding bouts occurred within 15min
of the previous response and the content of food was equal
to or greater than 0.01 g (Teuffel et al., 2015). If the interval
between meals was greater than 15min, the feeding bouts were
considered as a new meal. Meal parameters assessed in this
study encompassed bout size (g/bout), meal size (g/meal), bout
frequency (number/period), meal frequency (number/period),
inter-meal interval (min), meal duration (min/meal), eating rate
(mg/min), time spent in meals (%) as well as the satiety ratio
(min/g food eaten) calculated using the parameters described
above. These parameters were extracted from the software and
visualized using the Data Viewer (BioDAQ Monitoring Software
2.3.07, Research Diets Inc.). Data analysis was performed in Excel
(Microsoft). For better comparability between rats fed control




In the first experiment icv cannulated rats fed ad libitum
with standard rodent diet and accustomed to the food intake
monitoring system as described above were icv injected with
nesfatin-130−59 (0.1, 0.3, or 0.9 nmol/rat) or vehicle (5µl
ddH2O) directly before the onset of the dark phase. The
dose of nesfatin-130−59 was based on our previous study in
mice (Stengel et al., 2012a). The food intake microstructure
was assessed over a period of 24 h. The experiment was
repeated once in a crossover design; rats were allowed to
recover for 5 days in between the experiments. During two
experiments, behavior was determined by observation of the
locomotor activity and grooming (including washing and
licking).
In order to assess whether the effect of nesfatin-130−59 is
also mediated peripherally, naïve rats accustomed to the food
intake monitoring system, handled for ip injections and fed ad
libitum with standard rodent diet were injected ip with nesfatin-
130−59 (8.1, 24.3, or 72.9 nmol/kg) or vehicle (300µl saline)
directly before the dark phase started. These doses were based
on the observation that higher doses are required peripherally
compared to brain injections (Shimizu et al., 2009). Therefore,
up to 30-times higher doses were used peripherally compared
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to our icv experiments. The microstructure was assessed over a
period of 24 h. This experiment was repeated once in a crossover
design. Rats were allowed to recover for 5 days in between the
experiments.
Since the hypothalamic regulation of food intake is altered
under conditions of DIO (Velloso and Schwartz, 2011), we
also investigated the effect of nesfatin-130−59 on the food
intake microstructure in chronically icv cannulated DIO rats
accustomed to the food intake monitoring system and fed a
high fat diet. Nesfatin-130−59 (0.9 nmol/rat, dose based on first
experiment of the present study) or vehicle (5µl ddH2O) were
injected icv directly at the beginning of the dark phase and
the food intake microstructure was assessed over a period of
24 h. The experiment was repeated once in a crossover design
and rats were allowed to recover for 5 days in between the
experiments.
Statistical Analysis
Distribution of the data was determined by using the
Kolmogorov-Smirnov test. Data are expressed as mean ±
sem and were analyzed by One-way analysis of variance
(ANOVA) followed by Tukey post hoc test or Two-way or Three-
way ANOVA followed by the Holm–Sidak method. Differences
between groups were considered significant when p < 0.05
(SigmaStat 3.1., Systat Software, San Jose, CA, USA).
RESULTS
Nesfatin-130−59 Injected
Intracerebroventricularly at the Onset of
the Dark Phase Reduces Food Intake by
Decreasing Meal Size in Normal Weight
Rats
Nesfatin-130−59 (0.1, 0.3, or 0.9 nmol/rat) injected icv in normal
weight rats fed ad libitum with standard rodent diet induced a
dose-related reduction of dark phase food intake with a delayed
onset between the 4–8 h period post injection and observed at
a dose of 0.9 nmol/rat compared to vehicle (5µl ddH2O, −29%,
p < 0.05; Figure 1A). Therefore, this dose was used for all further
analyses. This reduction resulted in a decrease of cumulative food
intake which was observed over the 24-h measurement period
(−12% vs. vehicle, p < 0.05; Figure 1B) indicating a long-lasting
effect. Two-way ANOVA showed a significant influence of dose
[F(3, 239) = 11.2, p < 0.001] and time [F(5, 239) = 109.2,
p < 0.001].
Analysis of hourly food intake indicated that the main
anorexigenic effect occurred during the fifth hour post injection
with a −75% reduction of food intake following nesfatin-
130−59 compared to vehicle (p = 0.05; Figure 2). Moreover,
parameters of the first meal were mostly unaffected by icv
nesfatin-130−59 (Table 1) further pointing toward a delayed onset
FIGURE 1 | Nesfatin-130−59 reduces food intake for 24h in ad libitum fed normal weight rats. Nesfatin-130−59 injected intracerebroventricularly (0.1, 0.3,
and 0.9 nmol/rat) decreases dark phase food intake of standard rodent diet between the fourth and eighth hour and reduces cumulative food intake for 24 h post
injection at a dose of 0.9 nmol/rat. Food intake was measured by an automated episodic food intake monitoring system and expressed as food intake (kcal/300 g
bw)/4 h periods (A) and cumulative food intake over a period of 24 h (B). Each bar represents the mean ± sem. *p < 0.05 vs. vehicle.
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FIGURE 2 | Nesfatin-130−59 reduces food intake during the fifth hour post injection in normal weight rats. In rats fed ad libitum with standard rat diet,
nesfatin-130−59 injected intracerebroventricularly (0.1, 0.3, and 0.9 nmol/rat) induces a dose-related decrease in dark phase food intake during the fifth hour post
injection reaching significance at 0.3 and 0.9 nmol/rat. Food intake is expressed as hourly food intake (kcal/300 g bw) during the 4–8 h period post injection. Each bar
represents the mean ± sem. *p < 0.05 vs. vehicle.
TABLE 1 | Nesfatin-130−59 injected icv before the dark phase does not
alter the parameters of the first meal in ad libitum fed normal weight rats.
Parameter Group
Vehicle Nesfatin-130−59
(5µl ddH2O icv) (0.9 nmol icv)
Latency to first meal
(min)
2.09± 0.55 1.88±0.58
Size of first meal
(kcal/300 g bw)
5.85± 0.84 7.73±0.90
Duration of first meal
(min)
10.09± 1.64 13.54±1.68
Eating rate of first meal
(cal/300 g bw/min)
35.80± 3.94 29.69±2.86
Inter-meal interval (min) 46.71± 6.44 69.32±4.59*




icv, intracerebroventricular; mean ± sem; n = 10–11/group; *p < 0.05.
of the anorexigenic action. However, the interval following the
first meal was prolonged by nesfatin-130−59 compared to vehicle
(+48%, p < 0.05; Table 1). Due to the significant reduction of
food intake during the 4–8 h period post injection, the underlying
food intake microstructure was analyzed during this period.
Nesfatin-130−59 (0.9 nmol/rat icv) reduced meal size (−45%, p <
0.05; Figure 3B), meal duration (−54%, p < 0.05; Figure 3F),
and the time spent in meals (−41%, p < 0.05; Figure 3H),
while bout size (Figure 3A), bout frequency (Figure 3C), meal
frequency (Figure 3D), inter-meal intervals (Figure 3E), and
eating rate (Figure 3G) were not significantly affected compared
to vehicle (p > 0.05). At the same time, the satiety ratio was
increased following nesfatin-130−59 compared to vehicle injected
icv (+174%, p < 0.05; Figure 3I). Manual observation indicated
no abnormal behavior following icv injection of nesfatin-130−59
(data not shown).
Nesfatin-130−59 Injected Intraperitoneally
at the Onset of the Dark Phase Does Not
Reduce Food Intake or Alter the Food
Intake Microstructure of Normal Weight
Rats
Nesfatin-130−59 (8.1, 24.3, or 72.9 nmol/kg, ip) injected at higher
doses at the onset of the dark phase did not robustly reduce food
intake either expressed as food intake/period or cumulative food
intake compared to vehicle (p > 0.05; Table 2). Only the highest
dose (72.9 nmol/kg, ip) led to a slight and short-lasting reduction
of food intake during the seventh hour post injection compared
to vehicle (p < 0.05) that did not translate into a reduction of
cumulative food intake (p > 0.05; Table 2). Also analysis of the
food intake microstructure in the 4–8 h period (the period when
nesfatin-130−59 injected icv exerted its main effects) indicated no
alterations of microstructural parameters compared to vehicle
injected ip (p > 0.05; Table 3). Lastly, parameters of the first
meal were not affected by nesfatin-130−59 injected ip compared
to control (p > 0.05; Table 4).
Nesfatin-130−59 Injected
Intracerebroventricularly at the Onset of
the Dark Phase Reduces Food Intake by
Decreasing Meal Frequency of
Diet-induced-obese Rats Fed a High Fat
Diet
Rats fed a high fat diet (45% calories from fat) for a period of 10
weeks developed DIO and gained significantly more body weight
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FIGURE 3 | Nesfatin-130−59 reduces meal size, while meal frequency is not altered in normal weight rats. Nesfatin-130−59 (0.1, 0.3, and 0.9 nmol/rat) or
vehicle (5µl ddH2O) was injected intracerebroventricularly and the food intake microstructure assessed using an automated episodic food intake monitoring system.
Due to the strongest reduction in food intake, the dose of 0.9 nmol/rat was used for all further analyses. During the period of 4–8 h post injection, nesfatin-130−59
reduced meal size (B), meal duration (F) and the time spent in meals (H), while bout size (A), bout frequency (C), meal frequency (D), inter-meal intervals (E) and
eating rate (G) were not altered compared to vehicle. The satiety ratio was increased following nesfatin-130−59 (I). Each bar represents the mean ± sem. *p < 0.05
vs. vehicle.
TABLE 2 | Nesfatin-130−59 injected ip before the dark phase does not alter food intake in ad libitum fed normal weight rats.
Period Group
Vehicle (300µl saline ip) Nesfatin-130−59(8.1 nmol/kg ip) Nesfatin-130−59(24.3 nmol/kg ip) Nesfatin-130−59(72.9 nmol/kg ip)
FOOD INTAKE PER PERIOD (KCAL/300G BW)
0–4 h 41.15± 2.20 44.00± 2.47 44.42± 2.21 44.48± 2.22
4–8 h 27.70± 2.09 22.06± 2.54 25.80± 2.24 27.39± 1.78
8–12 h 13.15± 2.03 19.61± 2.10 15.56± 2.47 17.33± 2.24
12–16 h 0.47± 0.32 0.63± 0.45 1.59± 1.06 2.85± 1.48
16–20 h 1.21± 0.78 0.32± 0.28 1.31± 0.90 0.78± 0.71
20–24 h 12.51± 1.28 10.48± 0.81 12.54± 1.78 10.83± 0.91
CUMULATIVE FOOD INTAKE (KCAL/300G BW)
0–4 h 41.15± 2.20 44.00± 2.47 44.42± 2.21 44.48± 2.22
0–8 h 68.84± 2.56 66.05± 2.30 70.23± 2.33 71.86± 3.16
0–12 h 81.99± 2.76 85.67± 2.61 85.79± 2.74 89.19± 3.36
0–16 h 82.47± 2.69 86.29± 2.68 87.38± 2.44 92.05± 3.32
0–20 h 83.67± 2.79 86.62± 2.64 88.69± 2.35 92.82± 3.45
0–24 h 96.18± 2.91 97.09± 2.57 101.23± 2.36 103.65± 3.30
ip, intraperitoneal; mean ± sem; n = 14/group; p > 0.05.
compared to rats fed standard rodent diet (10% calories from
fat;+21% at 10 weeks, p < 0.01; Figure 4).
When injected icv in DIO rats, nesfatin-130−59 (0.9 nmol/rat)
induced a reduction of food intake during the 0–4 h period
post injection compared to vehicle (5µl ddH2O, −40%, p <
0.001; Figure 5A). This reduction resulted in a decrease of
cumulative food intake over a period of 20 h (−13% vs. vehicle,
p < 0.05; Figure 5B). Two-way ANOVA indicated a significant
influence of treatment [F(1, 131) = 36.3, p < 0.001] and time
[F(5, 131) = 53.4, p < 0.001]. Analysis of hourly food intake
during the 0–4 h period showed that the main anorexigenic
effect of nesfatin-130−59 occurred during the third and fourth
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TABLE 3 | Nesfatin-130−59 injected ip before the dark phase does not alter the food intake microstructure in the 4–8h period post injection in ad libitum
fed normal weight rats.
Parameter Group
Vehicle (300µl Nesfatin-130−59 Nesfatin-130−59 Nesfatin-130−59
saline ip) (8.1 nmol/kg ip) (24.3 nmol/kg ip) (72.9 nmol/kg ip)
Food intake 4–5 h (kcal/300 g bw) 5.96±2.13 6.09± 2.15 5.26± 2.06 8.35± 2.87
Food intake 5–6 h (kcal/300 g bw) 3.22±2.09 4.21± 1.98 6.95± 2.52 12.20± 3.31
Food intake 6–7 h (kcal/300 g bw) 14.18±3.34 5.76± 1.97 6.63± 2.89 4.29± 1.99*
Food intake 7–8 h (kcal/300 g bw) 4.34±2.00 6.00± 2.54 6.97± 2.25 2.53± 1.50
Bout size 4–8 h (kcal/300 g bw) 0.86±0.06 0.82± 0.07 0.87± 0.04 0.85± 0.05
Meal size 4–8 h (kcal/300 g bw) 17.01±2.39 14.32± 1.58 15.35± 2.25 18.55± 2.11
Bout frequency 4–8 h (number) 32.07±3.39 27.29± 1.99 31.00± 2.86 32.64± 2.83
Meal frequency 4–8 h (number) 1.93±0.22 1.71± 0.27 2.00± 0.23 1.71± 0.19
Inter-meal interval 4–8 h (min) 143.61±31.10 101.41± 18.08 147.27± 27.32 159.46± 31.92
Meal duration 4–8 h (min) 53.67±8.20 47.36± 7.52 48.12± 8.75 57.40± 7.42
Eating rate 4–8 h (cal/300 g
bw/min)
109.27±10.94 123.77± 11.05 107.61± 11.40 125.47± 18.96
Time spent in meals 4–8 h (%) 36.65±3.17 29.40± 3.94 31.89± 3.01 35.49± 3.43
Satiety ratio 4–8 h (min/kcal/300 g
bw food eaten)
8.17±1.08 7.73± 1.66 10.33± 1.41 8.47± 10.4
ip, intraperitoneal; mean ± sem; n = 14/group; *p < 0.05 vs vehicle.
TABLE 4 | Nesfatin-130−59 injected ip before the dark phase does not alter parameters of the first meal in ad libitum fed normal weight rats.
Parameter Group
Vehicle (300µl Nesfatin-130−59 Nesfatin-130−59 Nesfatin-130−59
saline ip) (8.1 nmol/kg ip) (24.3 nmol/kg ip) (72.9 nmol/kg ip)
Latency to first meal (min) 4.83± 2.24 9.23± 3.67 4.74± 1.84 7.40±5.39
Size of first meal (kcal/300 g bw) 11.08± 1.59 7.70± 0.85 8.55± 1.26 14.00±2.92
Duration of first meal (min) 21.15± 3.84 16.95± 3.24 17.70± 4.17 29.35±8.89
Eating rate of first meal (cal/300 g bw/min) 156.85± 12.37 152.62± 17.56 134.24± 13.45 176.78±17.44
Inter-meal interval (min) 48.17± 6.94 36.54± 4.90 43.12± 3.20 49.28±7.17
Satiety ratio after first meal (min/kcal/300 g bw food eaten) 5.04± 0.57 5.72± 1.19 9.08± 3.49 4.40±0.57
ip, intraperitoneal; mean ± sem; n = 14/group; p > 0.05.
hour post injection (−71 and −74%, respectively, compared to
vehicle, p < 0.05; Figure 6) pointing toward a delayed effect.
In line with this assumption, parameters of the first meal were
not significantly altered following nesfatin-130−59 compared to
vehicle (Table 5).
Based on the finding that nesfatin-130−59 already decreased
food intake in DIO rats during the 0–4 h period post injection,
the microstructure was analyzed during this period. Nesfatin-
130−59 (0.9 nmol/rat, icv) reduced bout frequency (−33%, p <
0.05; Figure 7C), meal frequency (−27%, p < 0.05; Figure 7D),
and eating rate (−35%, p < 0.01; Figure 7G), while bout size
(Figure 7A), meal size (Figure 7B), meal duration (Figure 7F),
and the time spent in meals (Figure 7H) were not significantly
affected compared to vehicle (p > 0.05). Moreover, inter-
meal intervals (+53%, Figure 7E) and the satiety ratio (+81%,
Figure 7I) were increased following icv injection of nesfatin-
130−59 (p < 0.01 vs. vehicle).
The combined analysis of food intake data of rats fed control
or high fat diet using Three-way ANOVA indicated a significant
influence of diet [F(1, 257) = 83.5, p < 0.001], time [F(5, 257) =
108.1, p < 0.001], and interaction of diet and time [F(5, 257) =
10.6, p < 0.001] as well as an interaction of treatment and time
[F(5,257) = 2.6, p < 0.05].
DISCUSSION
In the present study we investigated the effect of nesfatin-130−59
on feeding behavior in rats under normal weight and diet-
induced obese conditions. Nesfatin-130−59 injected icv reduced
dark phase food intake in normal weight rats fed a standard
rodent diet. This effect was delayed in onset as parameters of the
first meal were not altered with a maximum reduction of food
intake observed during the fifth hour post injection and long
lasting as it resulted in a reduction of cumulative food intake over
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FIGURE 4 | Rats fed a high fat diet develop diet-induced obesity. Rats
were ad libitum fed either a high fat diet (45% calories from fat, 35% from
carbohydrates, and 20% from protein, 4.7 kcal/g) or standard rodent diet (10%
calories from fat, 70% from carbohydrates, and 20% from protein, 3.9 kcal/g)
over a period of 10 weeks. Rats that gained most body weight (∼50%) were
selected for the following experiments as diet-induced obese (DIO) rats. DIO
rats showed greater body weight gain compared to rats fed standard rodent
diet. Data are expressed as mean ± sem. *p < 0.05 and **p < 0.01 vs. vehicle.
the 24 h observation period. These data are in accordance with a
previous study in rats where the main reduction following icv full
length nesfatin-11−82 was observed during the third hour post
injection and also observed over the whole measurement period
of 6 h (Stengel et al., 2009a). The difference in the onset of action
(third hour after nesfatin-11−82 vs. fifth hour after nesfatin-
130−59) may be due to differential diffusion capacities following
icv injection and—more importantly—differential interaction
with the yet unknown nesfatin-1 receptor. Lastly, also the
interaction with (an) additional receptor(s) has to be considered.
Interestingly, higher doses of nesfatin-130−59 were needed
to induce an anorexigenic effect. While nesfatin-11−82 injected
icv reduced food intake in rats following injection of 5 pmol,
nesfatin-130−59 exerted an anorexigenic effect after icv injection
of 0.9 nmol/rat. This difference is likely to result from differential
ligand-receptor interaction with full length nesfatin-11−82 being
more potent to induce the food intake inhibitory effect at low
doses. Whether the difference in potency is due to more selective
binding of nesfatin-11−82 to the receptor, slower dissociation or
a more potent stimulation of the receptor compared to nesfatin-
130−59 will have to be investigated in future studies. The effective
dose observed here in rats is comparable to the anorexigenic
doses described before in mice (0.3 and 0.9 nmol/mouse nesfatin-
130−59 icv; Stengel et al., 2012a).
After establishing nesfatin-130−59 also as an active fragment of
nesfatin-11−82 to reduce food intake in rats we investigated the
underlying food intake microstructure. Nesfatin-130−59 injected
icv reduced food intake by reducing meal size, while meal
frequency and inter-meal intervals were not altered. This pattern
indicates an increase of satiation (earlier termination of a meal),
whereas satiety (later initiation of a new meal after one meal
is completed) is not affected. This pattern is different from
the one observed before for mice where satiety (reduction in
meal frequency) was induced while satiation (meal size was not
altered) was not affected by icv nesfatin-130−59 (Stengel et al.,
2012a). This difference points toward species differences and
highlights the need for cautious translation of results from one
species to another. Interestingly, in mice full length nesfatin-
11−82 injected icv increased both satiation and satiety (Goebel
et al., 2011). This different pharmacodynamics is likely due to a
differential receptor binding of full length nesfatin-11−82 and its
active core, nesfatin-130−59.
Early on, the downstream signaling of NUCB2/nesfatin-
1 has been investigated. It has been shown that oxytocin
is involved in the mediation of nesfatin-11−82’s anorexigenic
effect as nesfatin-11−82 activates oxytocin containing neurons
in the paraventricular nucleus of the hypothalamus (PVN)
and central administration of the oxytocin-receptor antagonist,
H4928 abolished the food intake reduction induced by nesfatin-
11−82 in rats (Maejima et al., 2009). Moreover, an involvement of
proopiomelanocortin (POMC) and cocaine and amphetamine-
regulated transcript (CART) has been indicated as well based
on the following observations: First, nesfatin-130−59 was shown
to upregulate the mRNA expression of POMC and CART in
mice (Shimizu et al., 2009). Second, blockade of α-melanocyte
stimulating hormone (α-MSH) signaling, a major anorexigenic
cleavage product of POMC (Schwartz et al., 2000), using the
melanocortin receptor 3/4 antagonist, SHU9119 also blocked
nesfatin-11−82’s anorexigenic effect (Oh-I et al., 2006). Third,
brain ventricular injection of the melanocortin receptor 3/4
agonist, MTII decreased food intake by reducing meal size,
while no effect on meal frequency was observed (Azzara et al.,
2002; Berthoud et al., 2006), resembling the pattern of action
observed after icv injection of nesfatin-130−59 in the present
study. Since oxytocin increases the release of POMC in the
nucleus of the solitary tract (NTS), nesfatin-130−59 is likely to act
via an oxytocin→POMC→α-MSH/melanocortin receptor 3/4
pathway to inhibit food intake in rats.
Despite the fact that NUCB2/nesfatin-1 is predominantly
expressed in the stomach (Stengel et al., 2009b), the role of
peripheral NUCB2/nesfatin-1 is far from being clear. While one
study reported an anorexigenic effect following ip injection of
nesfatin-130−59 in mice (Shimizu et al., 2009), other studies in
rats (Stengel et al., 2009a), or mice (Goebel et al., 2011) did not
detect any effect. Similarly, in the present study we did not find
an anorexigenic effect of nesfatin-130−59 injected ip in normal
weight rats although up to 30-fold higher doses were used. This
difference may be due to species differences (mice vs. rats) or
different doses used (up to∼40 nmol/mouse vs.∼22 nmol/rat in
the present study). However, these findings clearly point toward a
central mode of action of nesfatin-1 to reduce food intake, while
peripheral nesfatin-1 is likely to have a different main effect such
as glucose control (Nakata and Yada, 2013).
Signaling of several food intake regulatory hormones is altered
under conditions of obesity (Hellström, 2013). These changes
encompass a decrease in circulating ghrelin levels (Ariyasu
et al., 2002) which may represent a compensatory action to
prevent further overeating. On the other side, the postprandial
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FIGURE 5 | Nesfatin-130−59 reduces food intake for 8 h in ad libitum fed diet-induced obese rats. Nesfatin-130−59 (0.9 nmol/rat) injected
intracerebroventricularly decreased dark phase food intake in the first 4 h period post injection, an effect that lasted for 8 h compared to vehicle (5µl dd H2O). Food
intake was assessed using an automated episodic food intake monitoring system and expressed as food intake (kcal/300 g bw)/4 h periods (A) and cumulative food
intake over a period of 24 h (B). Each bar represents the mean ± sem. *p < 0.05 vs. vehicle; **p < 0.01 vs. vehicle; ***p < 0.001 vs. vehicle.
FIGURE 6 | Nesfatin-130−59 reduces food intake in the third and fourth hour post icv injection in diet-induced obese rats. Nesfatin-130−59 injected
intracerebroventricularly (0.9 nmol/rat) decreased dark phase food intake in ad libitum fed rats during the third and fourth hour post injection compared to vehicle (5µl
dd H2O). Food intake was assessed using an automated episodic food intake monitoring system and expressed as food intake (kcal/300 g bw)/1 h periods. Each bar
represents the mean ± sem. *p < 0.05 vs. vehicle.
Frontiers in Neuroscience | www.frontiersin.org 9 November 2015 | Volume 9 | Article 422
Prinz et al. Nesfatin-130−59 Affects Feeding Microstructure in Rats
TABLE 5 | Nesfatin-130−59 injected icv before the dark phase does not alter parameters of the first meal in diet-induced obese rats fed ad libitum with
high fat diet.
Parameter Group
Vehicle (5µl ddH2O icv) Nesfatin-130−59 (0.9 nmol icv)
Latency to first meal (min) 14.74± 6.05 16.62± 9.99
Size of first meal (kcal/300 g bw) 5.98± 0.46 6.36± 0.89
Duration of first meal (min) 12.96± 3.11 13.54± 2.85
Eating rate of first meal (cal/300 g bw/min) 71.91± 8.76 60.26± 12.93
Inter-meal interval (min) 80.66± 9.92 128.10± 24.60
Satiety ratio after first meal (min/kcal/300 g bw food eaten) 13.76± 1.77 22.50± 5.00
icv, intracerebroventricular; mean ± sem; n = 11/group; p > 0.05.
FIGURE 7 | Nesfatin-130−59 decreases meal frequency, while meal size is not altered in diet-induced obese rats. DIO rats fed high fat diet were injected
intracerebroventricularly with nesfatin-130−59 (0.9 nmol/rat) or vehicle (5µl dd H2O) and the food intake microstructure assessed using an automated episodic food
intake monitoring system. During the period of 0–4 h post injection, nesfatin-130−59 reduced bout frequency (C), meal frequency (D), and eating rate (G), while bout
size (A), meal size (B), meal duration (F), and the time spent in meals (H) were not altered compared to vehicle. Inter-meal intervals (E) and the satiety ratio (I) were
increased following nesfatin-130−59. Each bar represents the mean ± sem. *p < 0.05 and **p < 0.01 vs. vehicle.
release of anorexigenic signals such as peptide YY (Xu et al.,
2011) is blunted under these condition which is likely to result
in reduced anorexigenic signaling. Therefore, we investigated
the effect of nesfatin-130−59 also in DIO rats fed a high fat
diet. The anorexigenic effect of nesfatin-130−59 was retained in
DIO rats with a delayed onset (parameters of the first meal
were not changed) and a long duration of action. Interestingly,
the main food intake inhibitory effect was already observed
during the third hour post injection (−71%), while in normal
weight rats the main reduction occurred later in the fifth hour
post nesfatin-130−59 icv injection (−75%). Moreover, the effect
translated into a reduction of food intake over a 20 h period
(−13%), while in normal weight rats the effect lasted for 20 h
(−12%). Lastly, the underlying food intake microstructure was
different in DIO rats compared to normal weight rats with a
decrease in meal frequency and an unaltered meal size under
conditions of high fat feeding indicating an increase of satiety
while satiation is not altered. Taken together, these findings give
rise to differential receptor binding, altered diffusion and—most
importantly—point toward a differential downstream signaling
under conditions of DIO compared to normal weight rats.
Interestingly, it was recently shown that rats fed a high
fat diet display significantly lowered plasma NUCB2/nesfatin-
1 levels (Haghshenas et al., 2014; Mohan et al., 2014).
Although the cellular action on the so far unknown receptor
is yet to be established, the chronically reduced circulating
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NUCB2/nesfatin-1 levels may result in a sensitization of the
receptor and lead to a stronger/more rapid response to icv
nesfatin-130−59. Early on, it was shown that nesfatin-11−82 acts
in a leptin-independent fashion (Oh-I et al., 2006; Maejima et al.,
2009). However, the corticotropin releasing factor (CRF) receptor
2, shown to play a role in nesfatin-11−82’s anorexigenic signaling
under normal weight conditions (Stengel et al., 2009a), may be
important under DIO conditions as well. An earlier study showed
that brain injection of the selective CRF2 agonist, urocortin 3
(1µg/rat) reduced food intake with a delayed onset (between
3 and 4 h) by decreasing meal frequency while meal size was
not altered in rats (Fekete et al., 2007), a pattern very similar to
the one observed following icv nesfatin-130−59 observed under
DIO conditions in the present study. The predominance of
the CRF2 downstream signaling pathway in the mediation of
nesfatin-130−59’s anorexigenic action might result from reduced
processing of POMC to α-MSH under conditions of obesity due
to reduced prohormone convertase two levels (Çakir et al., 2013).
In conclusion, these results provide pharmacological evidence
that nesfatin-130−59 is the active core of full length nesfatin-
11−82 also in rats that reduces food intake in normal weight
rats fed standard rodent diet as well as DIO rats fed a high
fat diet. Interestingly, the food intake microstructure differs
with an increase of satiation under normal weight and an
induction of satiety under DIO conditions. This may result
from a downstream nesfatin-130−59 → oxytocin→POMC→α-
MSH/melanocortin receptor 3/4 signaling in normal weight rats
while in DIO rats the nesfatin-130−59→CRF/CRF2 pathway may
predominate. The effect of nesfatin-130−59 is centrally mediated
as ip injection of higher doses had no effect. Therefore, the main
effect of peripheral nesfatin-1 remains to be established.
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